Bayer's Asundexian Receives FDA Priority Review for Secondary Stroke Prevention
Bayer AG announced that the U.S. FDA has granted priority review to its investigational oral Factor XIa inhibitor Asundexian for secondary stroke prevention. The decision follows positive Phase 3 OCEANIC‑STROKE data that met both efficacy and safety endpoints, positioning the drug as a potential new therapy for patients after non‑cardioembolic ischemic stroke or TIA.
ESR1 Mutation Testing Questions Follow Trial
A recent clinical trial examined the role of ESR1 mutations in advanced hormone‑receptor‑positive breast cancer, revealing that patients with the mutation respond differently to endocrine therapies. The study demonstrated that a next‑generation selective estrogen degrader (SED) extended progression‑free survival compared...
BioMarin Drug Acquired in Buyout Misses Goal in Rare Disease Study
BioMarin Pharmaceutical’s BMN 401, an enzyme‑replacement therapy for ENPP1 deficiency, met its primary biochemical endpoint by raising plasma PPi levels but failed the co‑primary skeletal health goal in a Phase 3 trial of 27 children. The miss on clinical benefit and all...
JCR Pharmaceuticals Highlights Preclinical CNS Gene Therapy Data for JUST-AAV Platform at ASGCT 2026
JCR Pharmaceuticals showcased preclinical data for its JUST‑AAV platform at ASGCT 2026, highlighting enhanced central nervous system (CNS) delivery and reduced liver exposure compared with conventional AAV9 vectors. The platform uses transferrin‑receptor‑targeted capsids to cross the blood‑brain barrier, delivering therapeutic...
Lessons Learned From Drug Development Programs in Autism: Implications for Future Programs
The article synthesizes expert insights on why autism drug development has lagged, highlighting the lack of approved therapies for core symptoms and the challenges posed by biological and clinical heterogeneity. It outlines six key learnings, including the need to measure...
OpenBind Unveils Its First AI Model for Drug Discovery
OpenBind, a UK‑led consortium, has published its first AI‑ready dataset and a predictive model for the EV‑A71 2A protease, a target linked to hand, foot and mouth disease. The release includes 699 X‑ray structures and binding‑strength data for 601 compounds,...
Wave Aims for Monthly Dosing with RNA Editing Treatment for AATD
Wave Life Sciences announced an updated read‑out from its early‑stage trial of an RNA‑editing therapy for alpha‑1 antitrypsin deficiency (AATD). The data indicate that the treatment can restore functional protein levels with a dosing schedule that could be moved to...
Relay Doubles the Bar, Outpacing Novartis with a 60% Response in Rare Disease
Relay’s oral PI3Kα inhibitor zovegalisib posted a 60% volumetric response in a Phase 2 trial of patients with vascular malformations, far outpacing Novartis’ 11% result with Vijoice. The data, presented at the ISVAA World Congress 2026, came from 20 evaluable patients,...
Colossal's 3D‑Printed Chick Incubator:
Colossal Biosciences has grown baby chicks inside 3D-printed plastic containers coated with a silicone-based membrane that mimics an eggshell's oxygen exchange — a meaningful step, but scientists say the company is overselling it.
FDA Approves Eli Lilly’s Foundayo, Pitting First Oral Obesity Pill Against Novo Nordisk’s Wegovy
Eli Lilly’s oral obesity medication Foundayo received FDA approval on April 1, becoming the first pill of its kind and setting up an immediate head‑to‑head battle with Novo Nordisk’s oral Wegovy. The two drugs differ in efficacy, manufacturing ease and safety profile,...
Accro Bioscience Secures $50 Million Series C Led by OrbiMed to Advance Ulcerative Colitis Drug
Accro Bioscience announced a $50 million Series C round headed by OrbiMed, with participation from TCGX, LAV, Cenova Capital and existing backers. The capital will finance a Phase IIb study of AC-101, a RIPK2 inhibitor targeting ulcerative colitis, underscoring private‑equity interest...
Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026
The FDA issued a warning letter to Harbin Jixianglong Biotech after a November 2025 inspection revealed multiple CGMP violations involving its peptide API manufacturing. The firm repackaged and relabeled semaglutide batches from unapproved suppliers, misbranding the products and failing to...
PolleyMed, LLC - 726018 - 05/14/2026
The FDA issued a warning letter to PolleyMed, LLC for marketing its SaniiSwab™ nasal cleaning product as an unapproved new drug and for misbranding claims of FDA OTC approval. The agency’s review of the company’s website and social‑media content found...
Sourav K. Mishra, M.D. / All India Institute of Medical Sciences - 724881 - 04/29/2026
The FDA issued a warning letter to Dr. Sourav K. Mishra of AIIMS Bhubaneswar for serious violations in a bioequivalence study of doxorubicin hydrochloride liposome injection conducted for Qilu Pharmaceutical. The investigator administered the prohibited CYP3A4 inhibitor aprepitant to all...
SERB Pays €115 Million for Hansa Biopharma’s Idefirix Rights in Europe and MENA
SERB Pharmaceuticals agreed to buy exclusive rights to Hansa Biopharma's kidney‑transplant drug Idefirix across Europe and the MENA region for €115 million ($124 million). The deal includes an upfront €110 million payment and a €5 million contingent payment tied to EMA approval, positioning SERB...
Sanofi's Efdoralprin Alfa Shows Triple Alpha‑1 Levels in Phase 2 AATD Emphysema Trial
Sanofi announced that its experimental drug efdoralprin alfa met the primary endpoint of its Phase 2 ElevAATe trial, delivering mean alpha‑1 antitrypsin trough levels more than three times higher than weekly plasma‑derived augmentation therapy. The result strengthens Sanofi’s rare‑disease portfolio and...
CDC Mobilizes Teams as Ebola Outbreak Claims 80 Lives in Eastern DRC
The World Health Organization declared a public health emergency after an Ebola outbreak in the Democratic Republic of Congo's Ituri province claimed roughly 80 lives. With 246 suspected cases and eight confirmed infections, the U.S. Centers for Disease Control and...
RAS Inhibition Enters Its Second Wave
RAS inhibition has moved into a second wave of drug development that goes beyond the KRAS G12C breakthrough. After sotorasib and adagrasib secured accelerated approvals for non‑small cell lung cancer and later for KRAS G12C‑mutated colorectal cancer, companies are targeting more prevalent...
STAT+: Eli Lilly Tops Prominent Rankings on Pharma R&D Performance
Eli Lilly topped the IDEA Pharma index, claiming the No. 1 spot in both Innovation and Invention categories. The Innovation ranking weighs revenue from new products, recent approvals and major development milestones, while the Invention ranking evaluates pipeline depth, clinical trial activity and...
FDA Approves First-Ever Gene Therapy For Deafness, Opening Door To New Era
The U.S. Food and Drug Administration has approved the world’s first gene therapy for deafness, targeting the OTOF mutation that blocks sound transmission in the inner ear. In a pivotal trial of 20 children and teens, 80% experienced improved hearing...
In the Clinic for May 19, 2026
BioWorld’s May 19, 2026 clinic roundup aggregates a wide array of industry snapshots, special reports, and infographics covering biopharma, med‑tech, and emerging health topics. The collection highlights trends such as dynamic digital data analysis, the 2026 med‑tech outlook, mRNA vaccine research, and...
BioMarin Suffers Another Blow to Rare Disease Portfolio in Phase 3 Flop
BioMarin’s investigational enzyme replacement therapy BMN 401 lowered plasma inorganic pyrophosphate (PPi) in the Phase 3 ENERGY 3 trial for ENPP1 deficiency, but it did not translate into clinical benefit. The study enrolled almost 30 children aged 1‑12 and missed the primary Radiographic...
SERB to Pay Hansa €110M Upfront for EU Rights to Kidney Transplant Drug
SERB Pharmaceuticals will pay Hansa Biopharma €110 million (≈$119 million) upfront for exclusive rights to Idefirix across Europe, the Middle East and North Africa. The antibody‑cleaving enzyme, conditionally approved for highly sensitized kidney‑transplant patients, generated €18.7 million (≈$20 million) in 2025 sales but has...
UC Maintenance Trials Drag On, Costs Soar
So uhhh, how long are these mega-expensive P3 UC maintenance studies going to have to be run for $SYRE? If only drug arm induction responders go onto maintenance (as is convention in P3 UC studies), how long do you need to...
Relay Drug Shows Early Promise for Rare Vascular Diseases
Relay drug shows early promise against rare blood vessel diseases https://t.co/WUJw7M1QDc $RLAY + 10% $NVS $OKUR
Cyclana Bio Granted Health Research Authority Approval
Cyclana Bio secured Health Research Authority and Research Ethics Committee approval for its 500‑patient observational study, PEMP, targeting endometriosis. The first participants have been enrolled at Peterborough City Hospital and the Rosie Hospital in Cambridge. Funded by a $6.3 million pre‑seed...
Bayer’s Hyrnuo (Sevabertinib) Gains the US FDA Priority Review for 1L Treatment of HER2-Mutated NSCLC
Bayer’s Hyrnuo (sevabertinib) received FDA priority review for first‑line treatment of adults with locally advanced or metastatic non‑small cell lung cancer (NSCLC) harboring HER2 kinase‑domain activating mutations and no prior systemic therapy. The review follows promising interim data from Cohort F...
Novastra Appoints Jarett Poll as CFO as OAP-101 Moves Toward Global Trials
Novastra Therapeutics announced the appointment of Jarett Poll as its fractional chief financial officer. The hire comes as the biotech ramps up preparation for global development of its lead cancer immunotherapy, OAP-101, aiming to secure new investor and partner relationships.
What It Takes to Run Rare Pediatric Disease Trials Across Borders: Insights From Polaryx Therapeutics
Polaryx Therapeutics is gearing up to test its oral candidate PLX-200 in a Phase II SOTERIA basket trial for four ultra‑rare lysosomal storage disorders—CLN2, CLN3, Krabbe and Sandhoff. The FDA has granted Fast Track designation for all four indications, promising closer...
Common Asthma Drug May Turn Off Tumor 'Switch' Tied to Immunotherapy Resistance
A Northwestern Medicine study published in Nature Cancer shows that blocking the cysteinyl leukotriene receptor 1 (CysLTR1) with the asthma drug montelukast can reverse immunotherapy resistance in several aggressive cancers. Experiments in mouse models and analyses of human tumor samples demonstrated...
Vaccine Experts Debate Options to Combat Outbreak of Unusual Ebola Strain
The World Health Organization convened a closed meeting of vaccine experts after the Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo was declared a public‑health emergency. The outbreak has produced roughly 500 suspected cases and more than 130...
A New Genetically Modified Rice Could Improve Children’s Health. But Will It Be Grown?
The Philippines has issued its first biosafety permit for HIZ039, a genetically modified rice enriched with iron and zinc, aiming to combat childhood anemia and stunting. Laboratory data show the grain triples iron and more than doubles zinc compared with...
VERTANICAL’s VER‑01 Gets FDA Breakthrough Therapy Designation for Chronic Low‑Back Pain
VERTANICAL announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to its oral pain drug VER‑01 for chronic low‑back pain. The designation speeds development and underscores the drug’s potential to address a massive unmet need for...
Neurocrine Biosciences Completes $2.9 Billion Soleno Acquisition
Neurocrine Biosciences has closed a $2.9 billion cash deal to acquire Soleno, bringing the hyperphagia drug VYKAT XR into its portfolio. The transaction was funded with a $53 per‑share tender offer and a new $1 billion revolving credit facility, positioning Neurocrine for growth...
AstraZeneca's Baxfendy Wins FDA Approval, Offering First‑In‑Class Hypertension Therapy
AstraZeneca announced FDA approval of Baxfendy (baxdrostat), the first aldosterone synthase inhibitor for hypertension. The drug cut systolic blood pressure by up to 9.8 mmHg in Phase III trials, targeting roughly 23 million U.S. patients whose blood pressure remains uncontrolled despite multiple medicines.
Protein Engineering and Testing Condensed Into One Day
Stanford researchers introduced MIDAS, a microbe‑independent deep assembly and screening method that reduces protein‑engineering cycles from weeks to a single day. By using PCR to assemble linear DNA fragments, the technique bypasses traditional bacterial cloning and plasmid preparation. The workflow...
Immune Checkpoint Regulation in Cancer Therapy and Evasion
The article reviews the multilayered regulation of immune checkpoint molecules, detailing genetic, epigenetic, transcriptional, post‑transcriptional, translational, and post‑translational mechanisms that shape checkpoint expression in tumors and immune cells. It highlights the recent clinical integration of LAG3‑targeted therapies as the newest...
MHRA’s Pound on Aligning Clinical Trial Regulation with Innovation
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is rolling out clinical‑trial reforms aimed at more than just faster approvals. Interim director of innovation James Pound says the agency is pursuing international alignment and horizon‑scanning to anticipate emerging therapies....
New Math Method Inflates Alzheimer’s Drug Success by 29x
A Brown University research letter published in JAMA Neurology warns that the statistical technique known as quantile aggregation can dramatically overstate the efficacy of emerging Alzheimer’s drugs. Simulations showed the method inflates the perceived link between amyloid clearance and cognitive...
Outlook Therapeutics Narrows Q2 Loss, Awaits FDA Decision on LYTENAVA in May 2026
Outlook Therapeutics announced a second‑quarter net loss of $4.45 million, a dramatic improvement from $46.35 million a year earlier. The biotech also signaled that the FDA will decide on its lead ophthalmic drug, LYTENAVA, in May 2026, a milestone that could reshape...
EU Approves Pfizer’s HYMPAVZI Gene Therapy for Hemophilia A/B with Inhibitors
The European Commission granted marketing authorization for Pfizer’s HYMPAVZI (marstacimab) to treat adults and adolescents with hemophilia A or B who have developed inhibitors. The approval follows a Phase 3 trial that showed a 93% drop in annualized bleeding rates versus...
Coya 302 Gets Fast-Track Designation for ALS Treatment
Coya Therapeutics received FDA fast‑track designation for its experimental ALS drug Coya 302, a subcutaneous blend of low‑dose IL‑2 and CTLA‑4 immunoglobulin. The therapy is designed to boost regulatory T‑cells while suppressing inflammatory monocytes, addressing the immune imbalance that accelerates motor‑neuron...
Atara Bounces Back with FDA
Atara Biotherapeutics saw its shares nearly double on May 7 after the FDA outlined a path for resubmitting its cell‑therapy candidate, tabelecleucel. The agency agreed to accept the single‑arm trial data in exchange for additional long‑term follow‑up, easing the regulatory deadlock...
Kazia’s Paxalisib Shows >50% CTC Drop, Early Responses
Kazia Therapeutics ($KZIA) is a catalyst-driven setup centered on upcoming ASCO data from their Paxalisib drug development platform. The update is following earlier disclosures from their ongoing Phase 1b ABC-Pax study evaluating paxalisib in metastatic triple-negative breast cancer (TNBC) showing...
Single VSV Vaccine Dose Shields Monkeys From Bundibugyo Ebola
Single Immunization With a Monovalent Vesicular Stomatitis Virus–Based Vaccine Protects Nonhuman Primates Against Heterologous Challenge With Bundibugyo ebolavirus https://t.co/ShMm7CSW0I
Developing a Drug To Reverse Heart Disease
Repair Biotechnologies’ lead candidate, REP-0004, is an mRNA‑based lipid nanoparticle designed to deliver a cholesterol‑degrading protein exclusively to hepatocytes. The FDA granted the drug orphan‑drug status and the company targets a Phase 1 start by mid‑2027, pending GMP manufacturing and IND‑enabling...
Uridine and Pyruvate Preserve T‑Cell Proliferation During Antibiotic Treatment
Uridine and pyruvate protect T cells’ proliferative capacity from mitochondrial toxic antibiotics: a clinical pilot study https://t.co/6NyObkztoA
Design Therapeutics to Unveil RESTORE-FA Gene Therapy Data as Shares Edge Higher
Design Therapeutics (DSGN) announced a webcast on May 18, 2026, to present Phase 1/2 RESTORE-FA trial data for its DT‑216P2 gene‑therapy candidate targeting Friedreich's ataxia. The move has drawn heightened investor attention as the company seeks to prove its novel...
Genentech Secures FDA Approval for Tecentriq in Muscle‑Invasive Bladder Cancer
Roche’s Genentech has won U.S. FDA approval for its immunotherapy Tecentriq as an adjuvant treatment for patients with muscle‑invasive bladder cancer guided by circulating tumor DNA. The decision adds a new therapeutic line for a disease with limited options and...
MSD's Sac-TMT Delivers in First Phase 3 Readout
Merck (MSD) reported that its TROP2‑targeting antibody‑drug conjugate sacituzumab tirumotecan (sac‑TMT), licensed from China’s Kelun‑Biotech, improved progression‑free and overall survival in a phase 3 trial for advanced or recurrent endometrial cancer. The TroFuse‑005 readout marks the first pivotal data for sac‑TMT...